Viracta VT3996-201, A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

September 17, 2018
https://clinicaltrials.gov/ct2/show/NCT03397706
Cancer - Lymphoma
Principal Investigator: Vijayalakshmi Donthireddy, MD
Epstein-Barr, lymphoid, Lymphoma, VRx3996, Valganciclovir
Accepting Participants